title: Lavender oil-potent anxiolytic properties via modulating voltage dependent calcium channels.
abstract: Recent clinical data support the clinical use of oral lavender oil in patients suffering from subsyndromal anxiety. We identified the molecular mechanism of action that will alter the perception of lavender oil as a nonspecific ingredient of aromatherapy to a potent anxiolytic inhibiting voltage dependent calcium channels (VOCCs) as highly selective drug target. In contrast to previous publications where exorbitant high concentrations were used, the effects of lavender oil in behavioral, biochemical, and electrophysiological experiments were investigated in physiological concentrations in the nanomolar range, which correlate to a single dosage of 80 mg/d in humans that was used in clinical trials. We show for the first time that lavender oil bears some similarities with the established anxiolytic pregabalin. Lavender oil inhibits VOCCs in synaptosomes, primary hippocampal neurons and stably overexpressing cell lines in the same range such as pregabalin. Interestingly, Silexan does not primarily bind to P/Q type calcium channels such as pregabalin and does not interact with the binding site of pregabalin, the α2δ subunit of VOCCs. Lavender oil reduces non-selectively the calcium influx through several different types of VOCCs such as the N-type, P/Q-type and T-type VOCCs. In the hippocampus, one brain region important for anxiety disorders, we show that inhibition by lavender oil is mainly mediated via N-type and P/Q-type VOCCs. Taken together, we provide a pharmacological and molecular rationale for the clinical use of the oral application of lavender oil in patients suffering from anxiety.
authors: Department of Pharmacology, Biocenter, Goethe University, Frankfurt, Germany.
authors: Anita M
authors: AM
authors: Schuwald
authors: Michael
authors: M
authors: Nöldner
authors: Thomas
authors: T
authors: Wilmes
authors: Norbert
authors: N
authors: Klugbauer
authors: Kristina
authors: K
authors: Leuner
authors: Walter E
authors: WE
authors: Müller
mesh_terms: D000818:Animals; D014151:Anti-Anxiety Agents / Q000494:pharmacology*; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D015220:Calcium Channels / Q000378:metabolism*; D005260:Female; D006624:Hippocampus / Q000166:cytology; D027523:Lavandula; D018782:Maze Learning / Q000187:drug effects; D051379:Mice; D009474:Neurons / Q000187:drug effects / Q000378:metabolism; D009822:Oils, Volatile / Q000494:pharmacology*; D010938:Plant Oils / Q000494:pharmacology*; D000069583:Pregabalin; D013574:Synaptosomes / Q000187:drug effects / Q000378:metabolism; D005680:gamma-Aminobutyric Acid / Q000031:analogs & derivatives / Q000494:pharmacology
chemical_list: D014151:Anti-Anxiety Agents; D002121:Calcium Channel Blockers; D015220:Calcium Channels; D009822:Oils, Volatile; D010938:Plant Oils; D000069583:Pregabalin; D005680:gamma-Aminobutyric Acid; C045718:lavender oil
references: Psychother Psychosom. 1996;65(1):14-23
references: 8838692
references: Pharmacol Res. 2000 Aug;42(2):177-82
references: 10887049
references: Pharmacol Biochem Behav. 2006 Dec;85(4):713-21
references: 17173962
references: Int J Neurosci. 2003 Jan;113(1):15-38
references: 12690999
references: FEBS Lett. 2000 Mar 24;470(2):189-97
references: 10734232
references: J Biol Chem. 1985 Mar 25;260(6):3440-50
references: 3838314
references: Biochem Pharmacol. 2003 Mar 1;65(5):843-56
references: 12628479
references: Hippocampus. 2013 Jan;23(1):40-52
references: 22815087
references: Neurosci Lett. 2008 Aug 8;440(3):299-303
references: 18579302
references: Wien Med Wochenschr. 2010 Dec;160(21-22):547-56
references: 21170695
references: J Psychopharmacol. 2011 Jan;25(1):3-16
references: 20530586
references: Phytomedicine. 2009 Apr;16(4):303-7
references: 18824339
references: J Neurophysiol. 1997 Jul;78(1):43-50
references: 9242259
references: J Neurosci. 2007 May 9;27(19):5179-89
references: 17494704
references: Physiol Behav. 2005 Sep 15;86(1-2):92-5
references: 16095639
references: J Pharmacol Exp Ther. 1999 Sep;290(3):1126-31
references: 10454486
references: Phytomedicine. 2010 Feb;17(2):94-9
references: 19962288
references: J Pharm Pharmacol. 2008 Nov;60(11):1515-22
references: 18957173
references: Annu Rev Biochem. 1994;63:823-67
references: 7979255
references: Neurochem Int. 2011 Aug;59(2):138-49
references: 21689704
references: Trends Pharmacol Sci. 2007 Feb;28(2):75-82
references: 17222465
references: Eur J Pharmacol. 2010 Oct 25;645(1-3):86-93
references: 20655301
references: Synapse. 2002 Sep 1;45(3):171-90
references: 12112396
references: Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17537-42
references: 17088553
references: J Ethnopharmacol. 2007 May 22;111(3):517-25
references: 17289317
references: Br J Pharmacol. 2005 May;145(1):75-83
references: 15723093
references: Phytother Res. 2001 Aug;15(5):422-5
references: 11507735
references: Neurochem Res. 1998 May;23(5):575-81
references: 9566594
references: Phytomedicine. 2007 Sep;14(9):613-20
references: 17482442
references: Eur J Pharmacol. 2011 Sep 30;667(1-3):80-90
references: 21651903
references: Eur J Pharmacol. 1993 Feb 15;244(3):293-301
references: 8384570
references: Neuropharmacology. 2002 Feb;42(2):229-36
references: 11804619
references: Mol Pharmacol. 2010 Mar;77(3):368-77
references: 20008516
references: Infect Immun. 1996 Feb;64(2):593-9
references: 8550212
references: Int Clin Psychopharmacol. 2010 Sep;25(5):277-87
references: 20512042
references: Hum Psychopharmacol. 2009 Jun;24(4):319-30
references: 19382124
references: Phytomedicine. 2012 Jun 15;19(8-9):665-71
references: 22475718
references: J Biol Chem. 1951 Nov;193(1):265-75
references: 14907713